Nuclear factor-kappa B and cancer: Its role in prevention and therapy

Biochemical Pharmacology

Volumn 64, Issue 5-6, 2002, Pages 883-888

  Bharti, Alok C ^a   Aggarwal, Bharat B ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoprevention; Chemosensitizaion; Nuclear factor B

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CAFFEIC ACID PHENETHYL ESTER; CAMPTOTHECIN; CAPSAICIN; CARCINOGEN; CELECOXIB; CIPROFIBRATE; CISPLATIN; COLECALCIFEROL; CURCUMIN; CYTARABINE; CYTOKINE; DAUNORUBICIN; DITHRANOL; DOXORUBICIN; ETOPOSIDE; HALOPERIDOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PROTEIN P50; PYRROLIDINE DITHIOCARBAMATE; QUERCETIN; RETINOID; SYNAPTOTAGMIN; TUMOR PROMOTER; UNINDEXED DRUG; VINBLASTINE; ZIDOVUDINE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CYTOPLASM; DNA BINDING; GENE ACTIVATION; HUMAN; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENS; CELL DIVISION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CHEMOPREVENTION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B;

EID: 0036709174     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01154-1     Document Type: Article

References (71)

1. Sen R., Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell. 47(6):1986;921-928.
2. Aggarwal BB, Vilcek J. Tumor Necrosis Factor: Structure, Function and Mechanism of Action. New York: Marcel Dekker Inc, 1992.
3. Shishodia S, Aggarwal BB. Nuclear factor-kappa B activation: A question of life and death. J Biochem Mol Biol 2002;35:28-40.
4. Collins T., Read M.A., Neish A.S., Whitley M.Z., Thanos D., Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 9(10):1995;899-909.
5. Chen F., Castranova V., Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am. J. Pathol. 159(2):2001;387-397.
6. Thanos D., Maniatis T. NF-kappa B: a lesson in family values. Cell. 80(4):1995;529-532.
7. Baeuerle P.A., Baltimore D. NF-kappa B: ten years after. Cell. 87(1):1996;13-20.
8. Baldwin A.S. Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14:1996;649-683.
9. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 18(49):1999;6853-6866.
10. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J. Biol. Chem. 274(39):1999;27339-27342.
11. Kabrun N., Enrietto P.J. The Rel family of proteins in oncogenesis and differentiation. Semin. Cancer Biol. 5(2):1994;103-112.
12. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 107(3):2001;241-246.
13. Yan Z., Subbaramaiah K., Camilli T., Zhang F., Tanabe T., McCaffrey T.A., Dannenberg A.J., Weksler B.B. Benzo[a]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. Evidence for the involvement of extracellular signal-regulated kinase and NF-kappaB. J. Biol. Chem. 275(7):2000;4949-4955.
14. Rioux N., Castonguay A The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-kappaB. Carcinogenesis. 21(9):2000;1745-1751.
15. Li N., Karin M. Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc. Natl. Acad. Sci. USA. 95(22):1998;13012-13017.
16. Baeuerle P.A., Lenardo M., Pierce J.W., Baltimore D. Phorbol-ester-induced activation of the NF-kappa B transcription factor involves dissociation of an apparently cytoplasmic NF-kappa B/inhibitor complex. Cold Spring Harb. Symp. Quant. Biol. 53(Pt 2):1988;789-798.
17. Abeyama K., Eng W., Jester J.V., Vink A.A., Edelbaum D., Cockerell C.J., Bergstresser P.R., Takashima A. A role for NF-kappaB-dependent gene transactivation in sunburn. J. Clin. Invest. 105(12):2000;1751-1759.
18. Wu M., Lee H., Bellas R.E., Schauer S.L., Arsura M., Katz D., FitzGerald M.J., Rothstein T.L., Sherr D.H., Sonenshein G.E. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J. 15(17):1996;4682-4690.
19. Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274(5288):1996;782-784.
20. Wang C.Y., Mayo M.W., Baldwin A.S. Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 274(5288):1996;784-787.
21. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 274(5288):1996;787-789.
22. Rath P.C., Aggarwal B.B. Antiproliferative effects of IFN-alpha correlate with the downregulation of nuclear factor-kappa B in human Burkitt lymphoma Daudi cells. J. Interferon. Cytokine Res. 21(7):2001;523-528.
23. Mukhopadhyay A., Bueso-Ramos C., Chatterjee D., Pantazis P., Aggarwal B.B. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene. 20(52):2001;7597-7609.
24. Garg A, Aggarwal BB. Nuclear transcription factor as a target for cancer drug development. Leukemia 2002;16:1053-68.
25. Mori N., Fujii M., Ikeda S., Yamada Y., Tomonaga M., Ballard D.W., Yamamoto N. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood. 93(7):1999;2360-2368.
26. Bargou R.C., Emmerich F., Krappmann D., Bommert K., Mapara M.Y., Arnold W., Royer H.D., Grinstein E., Greiner A., Scheidereit C., Dorken B. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 100(12):1997;2961-2969.
27. Bours V., Dejardin E., Goujon-Letawe F., Merville M.P., Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem. Pharmacol. 47(1):1994;145-149.
28. Giri D.K., Aggarwal B.B. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J. Biol. Chem. 273(22):1998;14008-14014.
29. Estrov Z., Manna S.K., Harris D., Van Q., Estey E.H., Kantarjian H.M., Talpaz M., Aggarwal B.B. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 94(8):1999;2844-2853.
30. Steele V.E., Sharma S., Mehta R., Elmore E., Redpath L., Rudd C., Bagheri D., Sigman C.C., Kelloff G.J. Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. J. Cell Biochem. Suppl. 26:1996;29-53.
31. Prasad A.V., Mohan N., Chandrasekar B., Meltz M.L. Activation of nuclear factor kappa B in human lymphoblastoid cells by low-dose ionizing radiation. Radiat. Res. 138(3):1994;367-372.
32. Han S.S., Chung S.T., Robertson D.A., Ranjan D., Bondada S. Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin. Immunol. 93(2):1999;152-161.
33. Clement M.V., Hirpara J.L., Chawdhury S.H., Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood. 92(3):1998;996-1002.
34. Nasi S., Ciarapica R., Jucker R., Rosati J., Soucek L. Making decisions through Myc. FEBS Lett. 490(3):2001;153-162.
35. Slawin K., Kadmon D., Park S.H., Scardino P.T., Anzano M., Sporn M.B., Thompson T.C. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras + myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res. 53(19):1993;4461-4465.
36. Boiko I.V., Mitchell M.F., Hu W., Pandey D.K., Mathevet P., Malpica A., Hittelman W.N. Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial. Clin. Cancer Res. 4(6):1998;1383-1391.
37. Tozawa K., Sakurada S., Kohri K., Okamoto T. Effects of anti-nuclear factor kappa B reagents in blocking adhesion of human cancer cells to vascular endothelial cells. Cancer Res. 55(18):1995;4162-4167.
38. Ambs S., Merriam W.G., Bennett W.P., Felley-Bosco E., Ogunfusika M.O., Oser S.M., Klein S., Shields P.G., Billiar T.R., Harris C.C. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 58(2):1998;334-341.
39. Marrogi A.J., Travis W.D., Welsh J.A., Khan M.A., Rahim H., Tazelaar H., Pairolero P., Trastek V., Jett J., Caporaso N.E., Liotta L.A., Harris C.C. Nitric oxide synthase cyclooxygenase 2 and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin. Cancer Res. 6(12):2000;4739-4744.
40. Chan M.M., Huang H.I., Fenton M.R., Fong D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem. Pharmacol. 55(12):1998;1955-1962.
41. Joseph I.B., Vukanovic J., Isaacs J.T. Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res. 56(15):1996;3404-3408.
42. Suganuma M., Okabe S., Kurusu M., Iida N., Ohshima S., Saeki Y., Kishimoto T., Fujiki H. Discrete roles of cytokines TNF-alpha, IL-1, IL-6 in tumor promotion and cell transformation. Int. J. Oncol. 20(1):2002;131-136.
43. Langenfeld J., Kiyokawa H., Sekula D., Boyle J., Dmitrovsky E. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc. Natl. Acad. Sci. USA. 94(22):1997;12070-12074.
44. Weinstein I.B., Begemann M., Zhou P., Han E.K., Sgambato A., Doki Y., Arber N., Ciaparrone M., Yamamoto H. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin. Cancer Res. 3(12 Pt 2):1997;2696-2702.
45. Philip S., Bulbule A., Kundu G.C. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J. Biol. Chem. 276(48):2001;44926-44935.
46. Heiss E., Herhaus C., Klimo K., Bartsch H., Gerhauser C. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J. Biol. Chem. 276(34):2001;32008-32015.
47. Oshima M., Murai N., Kargman S., Arguello M., Luk P., Kwong E., Taketo M.M., Evans J.F. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61(4):2001;1733-1740.
48. Kunz M., Hartmann A., Flory E., Toksoy A., Koczan D., Thiesen H.J., Mukaida N., Neumann M., Rapp U.R., Brocker E.B., Gillitzer R. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Am. J. Pathol. 155(3):1999;753-763.
49. Wang W., Abbruzzese J.L., Evans D.B., Chiao P.J. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene. 18(32):1999;4554-4563.
50. Pena J.C., Thompson C.B., Recant W., Vokes E.E., Rudin C.M. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer. 85(1):1999;164-170.
51. Diaz G.D., Paraskeva C., Thomas M.G., Binderup L., Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 60(8):2000;2304-2312.
52. Kondo S., Shinomura Y., Kanayama S., Higashimoto Y., Miyagawa J.I., Minami T., Kiyohara T., Zushi S., Kitamura S., Isozaki K., Matsuzawa Y. Over-expression of bcl-xL gene in human gastric adenomas and carcinomas. Int. J. Cancer. 68(6):1996;727-730.
53. Loukinova E., Chen Z., Van Waes C., Dong G. Expression of proangiogenic chemokine Gro 1 in low and high metastatic variants of Pam murine squamous cell carcinoma is differentially regulated by IL-1alpha EGF and TGF-beta1 through NF-kappaB dependent and independent mechanisms. Int. J. Cancer. 94(5):2001;637-644.
54. Surh Y.J., Han S.S., Keum Y.S., Seo H.J., Lee S.S. Inhibitory effects of curcumin and capsaicin on phorbol ester-induced activation of eukaryotic transcription factors NF-kappaB and AP-1. Biofactors. 12(1-4):2000;107-112.
55. Delia D., Aiello A., Formelli F., Fontanella E., Costa A., Miyashita T., Reed J.C., Pierotti M.A. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. Blood. 85(2):1995;359-367.
56. Singh S., Natarajan K., Aggarwal B.B. Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-kappa B activation by diverse agents. J. Immunol. 157(10):1996;4412-4420.
57. Sokoloski J.A., Hodnick W.F., Mayne S.T., Cinquina C., Kim C.S., Sartorelli A.C. Induction of the differentiation of HL-60 promyelocytic leukemia cells by vitamin E and other antioxidants in combination with low levels of vitamin D3: possible relationship to NF-kappaB. Leukemia. 11(9):1997;1546-1553.
58. Natarajan K., Manna S.K., Chaturvedi M.M., Aggarwal B.B. Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-kappaB, degradation of IkappaBalpha, nuclear translocation of p65 and subsequent gene expression. Arch. Biochem. Biophys. 352(1):1998;59-70.
59. Manna S.K., Mukhopadhyay A., Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B activator protein-1 and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164(12):2000;6509-6519.
60. Manna S.K., Mukhopadhyay A., Van N.T., Aggarwal B.B. Silymarin suppresses TNF-induced activation of NF-kappa B c-Jun N-terminal kinase and apoptosis. J. Immunol. 163(12):1999;6800-6809.
61. Manna S.K., Gad Y.P., Mukhopadhyay A., Aggarwal B.B. Suppression of tumor necrosis factor-activated nuclear transcription factor-kappaB activator protein-1, c-Jun N-terminal kinase and apoptosis by beta-lapachone. Biochem. Pharmacol. 57(7):1999;763-774.
62. Yamamoto Y., Yin M.J., Lin K.M., Gaynor R.B. Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem. 274(38):1999;27307-27314.
63. Nomura M., Ma W., Chen N., Bode A.M., Dong Z. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced NF-kappaB activation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Carcinogenesis. 21(10):2000;1885-1890.
64. Stark L.A., Din F.V., Zwacka R.M., Dunlop M.G. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 15(7):2001;1273-1275.
65. Natarajan K., Singh S., Burke T.R. Jr., Grunberger D., Aggarwal B.B. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc. Natl. Acad. Sci. USA. 93(17):1996;9090-9095.
66. Rao C.V., Kawamori T., Hamid R., Reddy B.S. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis. 20(4):1999;641-644.
67. Li J.J., Westergaard C., Ghosh P., Colburn N.H. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. Cancer Res. 57(16):1997;3569-3576.
68. Chainy G.B., Manna S.K., Chaturvedi M.M., Aggarwal B.B. Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappaB, AP-1, JNK, MAPKK and apoptosis. Oncogene. 19(25):2000;2943-2950.
69. Manna S.K., Sah N.K., Newman R.A., Cisneros A., Aggarwal B.B. Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase. Cancer Res. 60(14):2000;3838-3847.
70. Manna S.K., Aggarwal B.B. Wortmannin inhibits activation of nuclear transcription factors NF-kappaB and activated protein-1 induced by lipopolysaccharide and phorbol ester. FEBS Lett. 473(1):2000;113-118.
71. Kumar A., Dhawan S., Aggarwal B.B. Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-kappaB activation, IkappaB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells. Oncogene. 17(7):1998;913-918.